"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel ...
A total of 37 studies included real-world OS as an outcome; in these studies, median real-world OS ranged from 9 months to 23 ...
In this video, Kate H. Gessner, MD, PhD, discusses the mechanisms of immunotherapy failure in renal cell carcinoma, which was discussed during a case-based session at the 2025 American Society of ...
The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.
Panelists discuss how it would be preferred that BCG monotherapy not remain the first-line treatment for intermediate-risk and high-risk disease within the next 10 years. It is encouraged that the ...
"We really try to limit the amount of tissue we resect and what we do in patients who've had radiation," says Amy E. Krambeck, MD. In this video, Amy E. Krambeck, MD, discusses patient selection for ...
“It shows the significant poor outcomes in this population with our standard therapies and the need to improve upon that by developing novel treatments,” says Darren R. Feldman, MD. In this video, ...
18F-DCFPyL PET/CT shows high detection rates in biochemically recurrent prostate cancer with low PSA levels, suggesting its utility in early metastatic disease identification. The study included 129 ...
"We found that actually, many, many physicians were not reporting PSA doubling time," says Alicia Morgans, MD, MPH. In this video, Alicia Morgans, MD, MPH, gives an overview of the study “Impact of ...
The CLEAR trial demonstrated lenvatinib plus pembrolizumab's superior efficacy over sunitinib in advanced renal cell carcinoma, with robust response rates and significant tumor shrinkage. Sustained ...
Hear insights from experts on key trial data presented at ASCO GU 2025. In this video, Urology Times® highlights 5 interviews on key trial data presented at the 2025 American Society of Clinical ...
What advice do you have for urologists considering the adoption of newer treatment modalities for BCG-unresponsive NMIBC, especially in light of the positive clinical trial data?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results